Goldmann L, Duan R, Kragh T, et al. Oral Bruton tyrosine kinase inhibitors block activation of the platelet Fc receptor CD32a (FcγRIIA): a new option in HIT? Blood Adv. 2019;3(23):4021-4033.

doi:10.1182/bloodadvances.2019001362

Goldmann L, Duan R, Kragh T, et al. Oral Bruton tyrosine kinase inhibitors block activation of the platelet Fc receptor CD32a (FcγRIIA): a new option in HIT? Blood Adv. 2019;3(23):4021-4033.

Blood Adv (2020) 4 (1): 112.

https://doi.org/10.1182/bloodadvances.2019001362

The generic names of some drugs were omitted from the original supplemental data. The error has been corrected in the online data supplement.

2020

Goldmann L, Duan R, Kragh T, et al. Oral Bruton tyrosine kinase inhibitors block activation of the platelet Fc receptor CD32a (FcγRIIA): a new option in HIT? Blood Adv. 2019;3(23):4021-4033.

Contents

Data & Figures

Supplemental data

References

Cited By

Email alerts

ASH Publications

American Society of Hematology

Goldmann L, Duan R, Kragh T, et al. Oral Bruton tyrosine kinase inhibitors block activation of the platelet Fc receptor CD32a (FcγRIIA): a new option in HIT? Blood Adv. 2019;3(23):4021-4033.

Contents

Data & Figures

Supplemental data

References

Related

Related

Cited By

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only